1. Vadadustat was shown to be non-inferior to darbepoetin alfa in cardiovascular safety for patients with anemia and dialysis-dependent chronic kidney disease (DD-CKD).
2. Vadadustat was shown to present comparable efficacy in normalizing hemoglobin concentration compared to darbepoetin alfa in the patient population.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Chronic kidney...